ORGS News & Events

Orgenesis announced that its common stock will begin trading on the OTCQX Best Market under the ticker symbol "ORGS" following its delisting from the Nasdaq Stock Market. The delisting resulted from the Company's failure to meet the required stockholders' equity threshold. Orgenesis plans to attempt to resolve the deficiency and reapply for a Nasdaq listing as soon as practical.

Orgenesis Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on September 24, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on September 25, 2024, under the Company's existing trading symbol "ORGS". The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 68619K303. The Company filed a Certificate of Change with the Nevada Secretary of State on September 20, 2024 to effect the reverse split.

Orgenesis announced positive clinical trial results for a real-world study of CD19 CAR-T therapy, ORG-101, in patients with CD19+ Acute Lymphoblastic Leukemia. Harley Street Healthcare Group intends to set up a Global Cancer Initiative through its joint venture with Orgenesis, with a focus to democratize Advance Therapies and support further clinical development. The top-line efficacy and safety data from the study had a complete response of 82% in adult patients and 93% in pediatric patients. Moreover, the incidence of severe Cytokine Release Syndrome, a common safety concern associated with CAR-T therapies, was found to be low, 2% in adult patients and 6% in pediatric patients, compared to currently approved treatments. This suggests a favorable safety profile for ORG-101. CRS is a systemic reaction caused by an exaggerated immune response to immunotherapy, which is a significant safety issue in conventional CAR-T treatments.